CSL Ltd. won U.S. approval to sell a new drug for primary immunodeficiency. The Food and Drug Administration posted a notice announcing the approval of the biologic medicine, called Hizentra. The details are on the FDA website Web site.

Comments


Terms & Rules

As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use

Before using this Biomedical Investing website

OR